Trials / Completed
CompletedNCT04701788
A Clinical Trial to Evaluate the Immunogenicity and Safety of PPV23 Vaccine Revaccinations in the Elderly
A Phase Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine Revaccinations in the Elderly
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 331 (actual)
- Sponsor
- China National Biotec Group Company Limited · Industry
- Sex
- All
- Age
- 60 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the the immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly
Detailed description
1. Antibody double growth rate in 28-40 days after immunization; 2. Antibody GMC level in 28-40days after immunization; 3. Incidence of adverse reactions in 0-30days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 23-valent pneumococcal polysaccharide vaccine | The study group and the control group were injected with a dose of 23-valent pneumococcal polysaccharide vaccine. One month later, blood was collected and serum was separated. |
Timeline
- Start date
- 2021-03-30
- Primary completion
- 2021-12-20
- Completion
- 2022-02-15
- First posted
- 2021-01-08
- Last updated
- 2022-02-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04701788. Inclusion in this directory is not an endorsement.